Exir Bio
![](https://i0.wp.com/3rc.org/wp-content/uploads/2024/04/Exir-Bio-Logo.jpg?fit=300%2C120&ssl=1)
Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.
STEMCELL Technologies
![](https://i0.wp.com/3rc.org/wp-content/uploads/2024/04/Stemcell-logo.jpg?fit=592%2C254&ssl=1)
We are the world-leading provider of reagents and services for generating organoid and stem cell-derived models of healthy and diseased human tissues.
AnaBios
![](https://i0.wp.com/3rc.org/wp-content/uploads/2024/03/ANABIOS-LOGO-F.jpg?fit=450%2C195&ssl=1)
AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies, including superior quality human tissue samples and functional assays focused, as well as human primary cells through its subsidiary Cell Systems.
BiomimX
![](https://i0.wp.com/3rc.org/wp-content/uploads/2022/01/Screen-Shot-2022-01-18-at-3.18.40-PM.png?fit=575%2C253&ssl=1)
BiomimX develops the next generation of beating organs-on-chips. uBeat® Platforms and connected hardware provide 3D miniaturized constructs with a tunable mechanical stimulation to model human organs’ function and diseases. uBeat® products and customized drug screening services are available.
Aracari Bio
![](https://i0.wp.com/3rc.org/wp-content/uploads/2021/04/AracariS2.png?fit=800%2C336&ssl=1)
Aracari’s vascularized micro-organ and tumor models incorporate perfused human vasculature for the physiologic delivery of nutrients, drugs and immune cells to multiple tissue and tumor types. These powerful next-generation tools are advancing discovery in immuno-oncology and drug development.
Hesperos Inc.
![](https://i0.wp.com/3rc.org/wp-content/uploads/2021/04/HesperosS2-1.png?fit=800%2C336&ssl=1)
Hesperos is accelerating drug discovery by providing safety and efficacy testing services using its Human-on-a-Chip, microphysiological system. This breakthrough technology enables unprecedented preclinical insight bringing better therapies to patients faster without the need for animal testing.
Curi Bio
![](https://i0.wp.com/3rc.org/wp-content/uploads/2021/04/CuriS2.png?fit=800%2C336&ssl=1)
Curi’s suite of human iPSC-derived products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development.
MIMETAS
![](https://i0.wp.com/3rc.org/wp-content/uploads/2021/04/MimetasS2.png?fit=800%2C336&ssl=1)
Mimetas develops high-throughput healthy and diseased organ-on-a-chip models in the OrganoPlate®, a screening-compatible microfluidics platform that supports the recreation of native tissue structures, and their interaction with compounds, signaling factors, disease triggers, and co-cultured cell types.